Jennifer A. Moreton and H. Trevor Delves
Methods were developed to determine total B and 10B content in various biological samples, media and reagents by ICP-MS. Open vessel, wet ash digestion protocols using HNO3 were developed for the biological and media samples. Digestion of blood and plasma also required H2SO4. Despite relatively high blanks, instrumental detection limits using 3σ at or near the blank level were, for total boron (total B), <0.1 µmol l–1 (<1 µg l–1), and for 10B, <0.01 µmol l–1 (<0.1 µg l–1). Problems with variable blanks, matrix suppression and peak overlap by 12C on 11B are discussed. The developed methods were used to analyse samples for a collaborative study with Clinical Neurosciences at Southampton General Hospital, related to boron neutron capture therapy of brain tumours, of the uptake of 10B by tumour cells in vitro, using tissue culture, and in vivo, in the rat. Detection limits achieved in cells solubilised in 1 M NaOH and medium were <0.001 µmol ml–1 total B and <0.0001 µmol ml–110B and, for blood, 0.002 µmol g–1 total B and 0.0002 µmol g–110B, ∼10–9 M boronophenylalanine solutions. The analytical precision for duplicate analyses gave mean within-run RSDs of ∼7% for 10B concentration and <10% for total B concentration. The determination of 10B:11B ratios enabled statistically significant increases in 10B concentration to be detected and confirmed at low B levels where sample digests and digest blanks had similar B contents. Running 10B:11B ratios for standard and sample solutions were utilised for novel methods of calculating elevated 10B levels in the samples. Despite achieving low detection limits, elevated 10B levels could not be confirmed without the determination of 10B:11B ratios.